SRNE OTC
Sorrento Therapeutics, Inc.
1W: +0.0%
1M: +33.3%
3M: +14.3%
YTD: -74.6%
1Y: -77.1%
3Y: -96.1%
5Y: -99.3%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±52.7%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
11 relationships0
As Filer
counterparties named
11
As Counterparty
mentioned by others
2021-07-22
Earliest Filing
2024-02-27
Latest Filing
Mentioned As Counterparty
11 mentionsOther companies that named SRNE in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| SCLXW Scilex Holding Co | partner | Plaintiff in litigation regarding breach of restrictive covenant and trade secret misappropriation. | 2024-02-27 | View |
| SCLXW Scilex Holding Co | supplier | Seller of stock and warrants to the Company in a credit bid transaction | 2023-09-26 | View |
| ORMP ORAMED PHARMACEUTICALS INC. | acquirer | Seller of Scilex equity securities to Oramed Pharmaceuticals Inc. | 2023-08-22 | View |
| ORMP ORAMED PHARMACEUTICALS INC. | target | Seller of Scilex securities and debtor in bankruptcy proceedings | 2023-08-09 | View |
| SCLXW Scilex Holding Co | acquirer | Debtor in Chapter 11 bankruptcy proceedings receiving financing. | 2023-07-07 | View |
| SCLXW Vickers Vantage Corp. I | partner | Parent company of Scilex and counterparty in debt exchange and warrant transfer agreements | 2022-10-18 | View |
| SCLXW Vickers Vantage Corp. I | investor | Parent company of Scilex Holding Company and signatory to the Stockholder Agreement. | 2022-09-14 | View |
| SCLXW Vickers Vantage Corp. I | partner | Parent company of Scilex Holding Company; entered into Company Stockholder Support Agreement and Registration Rights Agr | 2022-03-21 | View |
| CELUW Celularity Inc | investor | Beneficial owner of 16.7% of Class A Common Stock via Subscription Agreement. | 2021-08-16 | View |
| DYAI DYADIC INTERNATIONAL INC | licensee | Entered into an exclusive license agreement to utilize Dyadic's C1 technology for vaccine and therapeutic development. | 2021-08-11 | View |
| CELUW Celularity Inc | investor | Subscriber that purchased shares of Company Class A Common Stock pursuant to a Subscription Agreement. | 2021-07-22 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR